Fahima Khan, PhD, is currently the Lead Global Trial Manager at Amgen, overseeing the Master protocol for KRAS G 12 C mutant trials in colorectal cancer, while also leading a first-in-human Immunotherapy BITE study for small cell lung cancer. Previous experience includes serving as Clinical Trial Manager at Carisma Therapeutics focused on cell therapy for solid tumors and as Lead Clinical Trial Monitor at the University of Maryland Medical System, where responsibilities included managing multi-center trials and leading a research data quality program in the radiation oncology department. Additional roles encompass Clinical Research Coordinator at The Princess Margaret Cancer Foundation, Assistant Professor at University Health Network, Clinical Research Associate at Qualia Clinical Research, and Postdoctoral Researcher at The Hospital for Sick Children. Educational qualifications include a Ph.D. in Cell Physiology from Niigata University Faculty of Medicine and an Honours degree in Biochemistry and Molecular Biology from the University of Dhaka.
This person is not in the org chart
This person is not in any teams
This person is not in any offices